Logo

sarcoma

Telix Pharmaceuticals Begins Phase I Trial of Radiopharmaceutical Agent in Sarcoma

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

Adaptimmune to File for Lete-Cel FDA Approval Following Cuts and Restructuring
Premium

The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential. 

Count Me In, Genome Medical Team up on Genetic Services for Rare Cancer Research Projects

Qualifying participants in two projects will be referred to Genome Medical for genetic counseling and will be offered optional clinical germline genetic testing.

Carrick Therapeutics Advances Second CDK Inhibitor Into Clinic, Explores Biomarker Approaches
Premium

The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.

FDA Clears Medigene's IND for TCR-T Therapy in Certain Advanced Solid Tumors

The firm plans to launch a Phase I trial for the autologous TCR-T cell therapy by year-end if additional funding comes through. 

Aug 16, 2024

'The Lead That Starts the Avalanche': Second Solid Tumor Cell Therapy Approval Energizes the Field
Premium

Aug 2, 2024

FDA Approves Adaptimmune's TCR Therapy Tecelra for Certain Synovial Sarcoma Patients

Apr 19, 2024

Ex Vivo Drug Screening Identifies Personalized Treatments for Most Pediatric Cancer Patients in Trial
Premium

Mar 28, 2024

Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium

Feb 12, 2024

Medigene to Study TCR-T Candidate in Certain Patients With Sarcomas, Gastric, Ovarian Cancers

Feb 2, 2024

Adaptimmune Therapeutics Seeking FDA Approval for Synovial Sarcoma T-Cell Therapy

Jan 25, 2024

Glenmark, Jiangsu Alphamab, 3D Medicines Ink Licensing Deal for Envafolimab

Jan 24, 2024

German Children's Cancer Center Aims to Expand Global Access to Methylation-Based Tumor Classifier
Premium

Sep 21, 2023

Princeton University Spinout KayoThera Marching Toward Clinic With Retinoid Pathway Inhibitor
Premium

Aug 10, 2023

Immatics Begins Phase I/II Trial of IMA402 in HLA-A*02:01-Positive Solid Tumors

Jun 6, 2023

Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas
Premium

Apr 5, 2023

Y-mAbs Launches Phase I Trial of GD2-Targeted Radioimmunotherapy

Mar 22, 2023

BostonGene, Little Warrior Foundation Partner to Develop Sarcoma-Specific Liquid Biopsy

Mar 21, 2023

Fusion Pharmaceuticals Begins Phase I Trial of Radiopharmaceutical in NTSR1-Expressing Tumors

Mar 1, 2023

CHLA Low-Pass WGS Liquid Biopsy Assay Could Aid Pediatric Cancer Diagnosis, Prognosis
Premium

Jan 26, 2023

Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors
Premium

Jun 29, 2022

Sarcoma Patients Should Receive Genomic Profiling More Often, Research Suggests
Premium

May 25, 2022

Umoja Biopharma Enters Clinical Stage With Seattle Children's CAR T-Cell Trial
Premium

May 16, 2022

Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada

Apr 11, 2022

Telix Acquires Exclusive Worldwide Rights to Eli Lilly's Olaratumab